- In April 2023, Bruker Corporation expanded its European operations by inaugurating a new high-performance mass spectrometry applications center in Bremen, Germany. This facility aims to enhance customer training, support, and instrument demonstrations for Bruker’s advanced mass spectrometry platforms, including its timsTOF and MALDI product lines. The investment highlights Bruker’s commitment to strengthening its presence in Europe while fostering collaborative research in proteomics, metabolomics, and clinical diagnostics
- In March 2023, Thermo Fisher Scientific launched a new version of its Orbitrap Exploris mass spectrometer tailored for biopharmaceutical applications at its R&D center in the U.K. The upgrade offers enhanced resolution and faster acquisition speeds to meet the growing demands of complex biologics characterization. This development underscores Thermo Fisher’s strategy to support Europe’s biopharma sector with precision analytical tools designed to comply with stringent regulatory requirements
- In February 2023, Agilent Technologies announced a collaboration with the University of Amsterdam to advance research in mass spectrometry-based metabolomics. The partnership focuses on using high-resolution mass spectrometry systems for data-rich applications in biomedical sciences and environmental toxicology. This initiative reinforces Agilent’s role in supporting academic research and demonstrates the growing influence of collaborative R&D efforts across Europe
- In January 2023, Waters Corporation introduced the Xevo TQ Absolute system across several European laboratories, including institutions in France and Italy. Designed to deliver ultra-sensitive quantitation with minimal sample volumes, this triple quadrupole mass spectrometer is gaining traction in pharmaceutical QA/QC workflows and clinical labs. The launch represents Waters' focus on developing high-efficiency instruments to meet the region's evolving analytical testing demands
- In January 2023, SCIEX partnered with the European Bioinformatics Institute (EMBL-EBI) to integrate advanced software tools with mass spectrometry platforms. This partnership aims to improve data analysis pipelines for proteomic and metabolomic research in public health and drug discovery. The collaboration reflects the increasing role of software-driven innovation in expanding the capabilities of MS systems across Europe
